肝脏转录组学揭示白介素-32是新型NAFLD相关细胞因子及候选生物标志物
该研究对125名肥胖个体进行肝脏转录组测序,按PNPLA3 I148M遗传风险变异分层。严重NAFLD患者中炎症和脂质代谢通路上调,IL32是最稳健上调基因,其循环水平与NAFLD及严重NAFLD独立相关,IL32-ALT-AST联合模型诊断NAFLD的AUC为0.92优于ALT-AST单独(0.81)。
要点
- PNPLA3 I148M携带状态与肝脏转录组两个主要变异成分相关并广泛影响基因表达。
- IL32在严重NAFLD中上调最稳健,其表达与脂肪变性严重程度相关。
- 循环IL32水平与NAFLD及严重NAFLD独立于转氨酶相关。
核心结论
- 肝脏IL32在NAFLD中过表达,与肝脏脂肪和肝损伤相关,可在循环中检测到,并与NAFLD的存在和严重程度独立相关。
研究设计与样本
- 对125名肥胖个体的肝脏转录组进行测序,按PNPLA3 I148M遗传风险变异分层。
- 严重NAFLD定义为存在脂肪性肝炎、NAFLD活动度评分≥4或纤维化分期≥2。
- 在77名严重肥胖个体及160名在肝病门诊评估的复制队列中,用ELISA测量循环IL32水平。
主要发现
- PNPLA3 I148M携带与肝脏转录组两个主要变异成分相关并广泛影响基因表达。
- 严重NAFLD患者中炎症和脂质代谢通路上调。
- IL32是严重NAFLD组中最稳健上调的基因(校正p=1×10-6),其表达与脂肪变性严重程度相关,在I148M变异携带者和非携带者中均如此。
- 在77名严重肥胖个体和160名复制队列个体中,循环IL32水平与NAFLD及严重NAFLD独立于转氨酶相关(两者p<0.01)。
- IL32-ALT-AST线性组合在NAFLD诊断中表现优于ALT-AST单独(曲线下面积=0.92 vs 0.81,p=5×10-5)。
关键数值与推荐
- 严重NAFLD定义:存在脂肪性肝炎、NAFLD活动度评分≥4或纤维化分期≥2。
- IL32在严重NAFLD组中校正p=1×10-6。
- 循环IL32与NAFLD及严重NAFLD独立于转氨酶相关,两者p<0.01。
- IL32-ALT-AST联合诊断NAFLD的曲线下面积=0.92,ALT-AST单独为0.81,p=5×10-5。
临床怎么用
- 循环IL32水平可作为NAFLD及其严重程度的候选非侵入性生物标志物。
- IL32-ALT-AST联合模型可能提高NAFLD诊断性能,优于单独使用ALT-AST。
- PNPLA3 I148M分层有助于理解NAFLD转录组异质性及IL32表达。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Efforts to manage non-alcoholic fatty liver disease (NAFLD) are limited by the incomplete understanding of the pathogenic mechanisms and the absence of accurate non-invasive biomarkers. The aim of this study was to identify novel NAFLD therapeutic targets andbiomarkers by conducting liver transcriptomic analysis in patients stratified by the presence of the PNPLA3 I148M genetic risk variant. DESIGN: We sequenced the hepatic transcriptome of 125 obese individuals. 'Severe NAFLD' was defined as the presence of steatohepatitis, NAFLD activity score ≥4 or fibrosis stage ≥2. The circulating levels of the most upregulated transcript, interleukin-32 (IL32), were measured by ELISA. RESULTS: Carriage of the PNPLA3 I148M variant correlated with the two major components of hepatic transcriptome variability and broadly influenced gene expression. In patients with severe NAFLD, there was an upregulation of inflammatory and lipid metabolism pathways. IL32 was the most robustly upregulated gene in the severe NAFLD group (adjusted p=1×10-6), and its expression correlated with steatosis severity, both in I148M variant carriers and non-carriers. In 77 severely obese, and in a replication cohort of 160 individuals evaluated at the hepatology service, circulating IL32 levels were associated with both NAFLD and severe NAFLD independently of aminotransferases (p<0.01 for both). A linear combination of IL32-ALT-AST showed a better performance than ALT-AST alone in NAFLD diagnosis (area under the curve=0.92 vs 0.81, p=5×10-5). CONCLUSION: Hepatic IL32 is overexpressed in NAFLD, correlates with hepatic fat and liver damage, and is detectable in the circulation, where it is independently associated with the presence and severity of NAFLD.
引用
- Baselli GA, Dongiovanni P, Rametta R, et al. Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut. 2020. PMID: 32001554. doi:10.1136/gutjnl-2019-319226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。